2,421 results
P
Hepatocellular carcinomas (HCCs), non-HCC malignancies
I/C
Contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System category M (LR-M), CEUS LR-M category, Non-HCC malignancies
O
Proportion of CEUS LR-M in HCC and non-HCC malignancies, Frequency of individual CEUS LR-M imaging features
P
Oral anticoagulants (OAC), P-glycoprotein (P-gp)/CYP3A4 enzyme
I/C
P-gp/CYP3A4 inhibitors, Rivaroxaban, Dabigatran, Apixaban, Edoxaban, Warfarin
O
Major bleeding, Gastrointestinal (GI) bleeding, Stroke/systemic embolism (SE), All-cause mortality, Any bleeding, Intracranial hemorrhage (ICH)
P
soil microbial extracellular hydrolytic enzymatic activities (Hy-EEAs), soil oxidative enzymatic activities (Ox-EEAs), soil carbon (C), soil nitrogen (N), soil phosphorus (P)
I/C
natural forest conversion (NFC), Changes in soil Hy- and Ox-EEAs, changes in soil organic C, available P, microbial biomass C and N
O
depletion of soil organic carbon, stimulated soil microbial secretion of Hy- and Ox-EEAs, soil total N scarcity, provoke soil microbial Hy-EEAs, soil total P dearth, quickened the soil Ox-EEAs, plenitude of soil available P, suppressed soil Hy- and Ox-EEAs
P
patients with liver lesions
I/C
LI-RADS algorithm, original studies reporting probability of LR-M for HCC and non-HCC malignancy on MRI
O
pooled percentages of HCC and non-HCC malignancy for LR-M, sources of heterogeneity between reported results
P
patients with cancers
I/C
F-NLR scoring system, high F-NLR score vs. low F-NLR score
O
overall survival (OS) and disease-free survival (DFS)/progression-free survival (PFS)
P
patients with recurrent or metastatic head and neck squamous cell carcinomas (R/M HNSCC)
I/C
PD-1/PDL-1 inhibitors, anti-EGFR agents, cetuximab, panitumumab, control, platinum-resistant disease, methotrexate, platinum-based regimens
O
overall survival (OS), progression-free survival (PFS), overall response rates (ORR)
P
Asian people living with HIV
I/C
switching to bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF), staying on baseline regimens
O
maintained 100% virological suppression at week 48 with no treatment-emergent drug resistance and safety profiles comparable to those seen in people who stayed on baseline regimens
P
variable ZMA fractures, M-shape ZMA fractures
I/C
intraoperative imaging (IOI), conventional methods without IOI (N-IOI)
O
reduction adequacy of ZMA fractures, postoperative correction, symmetry, appearance satisfaction
P
knee articular cartilage defect, osteoarthritis
I/C
human umbilical-cord-blood-derived mesenchymal stem cells (hUCB-MSCs), bone marrow aspiration concentrate (BMAC)
O
International Knee Documentation Committee (IKDC) score, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores, visual analog scale (VAS) score, modified Magnetic Resonance Observation of Cartilage Repair Tissue (M-MOCART) score
P
NSCL/P patients, controls
I/C
MTHFR A1298C polymorphism, allele, homozygote, heterozygote, dominant, and recessive models
O
association between A1298C polymorphism and NSCL/P risk